In 537 adults with type 2 diabetes on diet and exercise alone, weekly retatrutide 4, 9 or 12 mg lowered HbA1c at 40 weeks by 0·88–1·12% more than placebo; bodyweight fell 11·5–15·3% vs 2·6% (key secondary). Discontinuation for adverse events 2–5% vs 0%.
RCTn = 537
Bajaj et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial